Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round. The investment will enable the company to scale its base, operations and commercial launches in the UK and USA, accelerate its research and development, and expand its platform into personalized therapy decisions, integrating imaging with molecular data, robotics, and liquid biopsies.